Login

Ownership

13F as of Q2 2026 · 39.6M shares outstanding

Who owns Keenova Therapeutics plc?

By type of holder
Institutions 0.0% Everyone else 100.0%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 7 holders own 117.6%
Steven A. Tananbaum 22.4% · GoldenTree Asset Management LP 22.3%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q2 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Keenova Therapeutics plc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2014–FY2025
−56.9%
−8.92% a year
Each share's claim on the business
+131.8%
grew without buying or selling a share
Spent on buybacks vs paid in stock
$1.47B vs $441M
over 10 fiscal years
Diluted shares, split-adjusted
19.2M68.8M118.4M2014: 64.9M shares'142015: 117.2M shares'152016: 111.5M shares'162017: 97.9M shares'172018: 84.0M shares'182019: 83.9M shares'192020: 84.5M shares'202021: 84.7M shares'212024: 19.8M shares'242025: 28.0M shares'25
Buybacks Stock-based comp
$0$326.5M$652.9M2014 buybacks: $17.5M2014 stock comp: $67.7M'142015 buybacks: $92.2M2015 stock comp: $117.0M'152016 buybacks: $652.9M2016 stock comp: $42.9M'162017 buybacks: $651.7M2017 stock comp: $59.2M'172018 buybacks: $57.5M2018 stock comp: $34.6M'182019 buybacks: $2.6M2019 stock comp: $33.8M'192020 buybacks: $400.0K2020 stock comp: $25.3M'202021 buybacks: $02021 stock comp: $10.2M'212024 buybacks: $02024 stock comp: $6.7M'242025 buybacks: $02025 stock comp: $43.7M'25

How patient are the owners?

No 13F manager reports holding Keenova Therapeutics plc.

Super Investors

Investment managers reporting Keenova Therapeutics plc on Form 13F
No 13F manager reports holding Keenova Therapeutics plc yet.

Institutional Funds

Mutual funds and ETFs reporting Keenova Therapeutics plc on Form N-PORT; together they hold 0.0% of the company
AS
Investment Managers Series Trust II
Position value
$43.9K
% of company
0.00%
% of the fund
0.09%
As of
July 31, 2026
FC
Advisors' Inner Circle III
Position value
$5.4K
% of company
0.00%
% of the fund
0.01%
As of
June 30, 2026

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
SA
Steven A. Tananbaum
5%+ holder13D · 22.4%
Shares
8.9M
% of company
22.41%
Change vs last qtr
—
Held since
—
GA
GoldenTree Asset Management LP
5%+ holder13D · 22.3%
Shares
8.8M
% of company
22.28%
Change vs last qtr
—
Held since
—

5 more holders behind a free account

See every insider and 5%+ holder of Keenova Therapeutics plc.

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support